The importance of exogenous antigen in priming the human CD8+ T cell response: Lessons from the EBV nuclear antigen EBNA11

Journal of Immunology

Volumn 165, Issue 12, 2000, Pages 7078-7087

  Blake, N ^a   Haigh, T ^a   Shaka'a, G ^a   Croom Carter, D ^a   Rickinson, A ^a  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CD8 ANTIGEN; CELL NUCLEUS ANTIGEN; EPITOPE; GAMMA INTERFERON; HLA B ANTIGEN; HLA B53 ANTIGEN; HLA B7 ANTIGEN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; UNCLASSIFIED DRUG; VIRUS ANTIGEN;

ANTIGEN PRESENTATION; ARTICLE; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOKINE RELEASE; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; EPSTEIN BARR VIRUS; HUMAN; HUMAN CELL; IN VITRO STUDY; INFECTIOUS MONONUCLEOSIS; LYMPHOCYTE ACTIVATION; MEMORY CELL; PRIORITY JOURNAL; T LYMPHOCYTE SUBPOPULATION;

EID: 0034671572     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.165.12.7078     Document Type: Article

References (40)

1. Mechanisms of MHC class-I restricted antigen presentation
2. Cytotoxic T-cell immunity to virus-infected non-haematopoietic cells requires presentation of exogenous antigen
3. Cytotoxic T lymphocyte activation by cross-priming
4. + T cell responses to infectious agents, tumors, transplant, and vaccines
5. 5 and CD36, and cross-present antigens to cytotoxic T lymphocytes
6. Constitutive macropinocytosis allows TAP-dependent major histocompatibility complex class I presentation of exogenous soluble antigen by bone marrow-derived dendritic cells
7. Dendritic cells and the control of immunity
8. + T cell help
9. Help for inducing cytotoxic T cell responses by cross-priming is mediated via CD40 signalling
10. T-cell help for cytotoxic T lymphocytes is mediated by CD40-CD40L interactions
11. Epstein-Barr virus
12. Human cytotoxic T lymphocyte responses to Epstein-Barr virus infection
13. Epitope focusing in the primary cytotoxic T cell response to Epstein-Barr virus and its relationship to T cell memory
14. Identification of target antigens for the human cytotoxic T cell response to Epstein-Barr virus (EBV) implications for the immune control of EBV-positive malignancies
15. Localization of Epstein-Barr virus cytotoxic T cell epitopes using recombinant vaccinia implications for vaccine development
16. Inhibition of antigen processing by the internal repeat region of the Epstein-Barr virus nuclear antigen-1
17. Inhibition of ubiquitin/proteasome-dependent protein degradation by the Gly-Ala repeat domain of the Epstein-Barr virus nuclear antigen 1
18. + T cell responses to EBV EBNA1 HLA class I presentation of the (Gly-Ala)-containing protein requires exogenous processing
19. Identification of EBNA1 amino acid sequences required for the interaction of the functional elements of the Epstein-Barr virus latent origin of DNA replication
20. + memory T cells
21. + T cells during the primary immune response to Epstein-Barr virus in vivo
22. Phenotypic analysis of antigen specific T lymphocytes
23. MHC ligands and peptide motifs first listing
24. Molecular analysis of the association of HLA-B53 and resistance to severe malaria
25. Antigen-specific interaction between T and B cells
26. Viral strategies of immune evasion
27. Cytomegaloviral control of MHC class I function in the mouse
28. Cytokines restore MHC class I complex formation and control antigen presentation in human cytomegalovirus-infected cells
29. Murine cytotoxic T lymphocytes recognize an epitope in an EBNA-1 fragment, but fail to lyse EBNA-1-expressing mouse cells
30. Major histocompatibility complex class I presentation of peptides derived from soluble exogenous antigen by a subset of cells engaged in phagocytosis
31. + T lymphocytes consistently respond to the latent Epstein-Barr virus nuclear antigen EBNA1
32. An altered positron of the α2 helix of MHC class I is revealed by the crystal structure of HLA-B*3501
33. Bound water structure and polymorphic amino acids act together to allow the binding of different peptides to MHC class I HLA-B53
34. Nonresponsiveness to an immunodominant Epstein-Barr virus-encoded cytotoxic T-lymphocyte epitope in nuclear antigen 3A implications for vaccine strategies
35. Identification of cytotoxic T cell epitopes within Epstein-Barr Virus (EBV) oncogene latent membrane protein 1 (LMP1) evidence for HLA A2 supertype-restricted immune recognition of EBV-infected cells by LMP1-specific cytotoxic T lymphocytes
36. Antibodies to Epstein-Barr virus-associated nuclear antigen in infectious mononucleosis
37. Antibody responses to Epstein-Barr virus-determined nuclear antigen (EBNA)-1 and EBNA-2 in acute and chronic Epstein-Barr virus infection
38. Clonal transformation of adult human leukocytes by Epstein-Barr virus
39. Sequential appearance of Epstein-Barr virus nuclear antigen and lymphocyte-detected membrane antigens in B cell transformation
40. Immunodominance among EBV-derived epitopes restricted by HLA-B27 does not correlate with epitope abundance in EBV-transformed B-lymphoblastoid cell lines